8-K: CAMP4 Therapeutics Presents Promising Data on SYNGAP1 and Urea Cycle Disorders Programs

CAMP4 Therapeutics shares positive translational data for its SYNGAP1-related disorders program and preclinical/clinical data for its Urea Cycle Disorders program at the American Society of Gene and Cell Therapy Annual Meeting.

Summary

• CAMP4 Therapeutics presented data on its SYNGAP1-related disorders and Urea Cycle Disorders (UCDs) programs at the 28th Annual Meeting of the American Society of Gene and Cell Therapy.
• In haploinsufficient mice, CMP-SYNGAP-01 restored SYNGAP1 protein levels and rescued motor and spatial learning defects.
• In non-human primates (NHPs), CMP-SYNGAP-01 led to a ~1.5-fold increase in SYNGAP1 protein levels in relevant brain regions.
• Preclinical data for the UCD program showed that CMP-CPS-001 resulted in dose-dependent reductions in ammonia levels in Otc-deficient mice.
• In NHPs, CMP-CPS-001 administration resulted in up to a 40% increase in ureagenesis.
• Phase 1 clinical data for CMP-CPS-001 in healthy volunteers showed that it was well tolerated, with no serious adverse events.
• Pharmacokinetic data showed a dose-dependent increase in exposure to CMP-CPS-001.
• The company anticipates expanding into OTC heterozygotes to assess the safety and effect of CMP-CPS-001 on ureagenesis.

Sentiment

Score: 8

Explanation: The document presents positive preclinical and clinical data, suggesting potential for the company's therapeutic programs. The management's comments are optimistic, and the company is moving forward with clinical trials and exploring strategic partnerships.

Positives

• CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels in relevant brain regions in non-human primates.
• CMP-CPS-001 was well tolerated in the Phase 1 clinical trial, with no serious adverse events.
• Preclinical data showed promising results for both the SYNGAP1 and UCD programs.
• The company is planning to expand the CMP-CPS-001 trial into OTC heterozygotes.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the uncertainty of clinical development and the need for additional financing.
• The company's limited operating history and incurrence of substantial losses are also risks.
• There are risks related to the manufacturing of the company's product candidates and the company's reliance on third parties.
• The company's ability to obtain and maintain sufficient intellectual property protection is also a risk.

Future Outlook

The company anticipates expansion into OTC heterozygotes to assess safety and CMP-CPS-001 effect on ureagenesis in patients with evidence of reduced urea cycle function, and expects to initiate GLP toxicity studies for the SYNGAP1 program in 2025.

Management Comments

• Dan Tardiff, Ph.D., stated that the data indicate CMP-SYNGAP-01 can restore SYNGAP1 protein levels and that the UCD clinical candidate is well tolerated.
• Josh Mandel-Brehm, Chief Executive Officer of CAMP4, added that the data underscore the expansive potential of their RAP Platform and that they look forward to progressing toward additional clinical trials and exploring strategic partnerships.

Industry Context

This announcement positions CAMP4 as a key player in the development of RNA-targeting therapeutics for genetic diseases, particularly those characterized by haploinsufficiency or recessive loss of function. The focus on SYNGAP1 and Urea Cycle Disorders addresses significant unmet needs in neurologic and metabolic disorders.

Comparison to Industry Standards

• The approach of upregulating gene expression using regulatory RNA-targeting ASOs is a novel strategy compared to traditional gene therapies or enzyme replacement therapies.
• Other companies are developing therapies for SYNGAP1-related disorders, but CAMP4's approach of directly increasing SYNGAP1 protein levels is unique.
• For Urea Cycle Disorders, current treatments primarily focus on managing ammonia levels through nitrogen scavengers and dietary restrictions, while CAMP4's CMP-CPS-001 aims to address the underlying cause of the disease by increasing ureagenesis.

Stakeholder Impact

• The positive data could benefit shareholders by increasing the company's value.
• Patients with SYNGAP1-related disorders and Urea Cycle Disorders could benefit from potential new treatment options.
• Employees may benefit from the company's progress and potential growth.

Next Steps

• The company anticipates expansion into OTC heterozygotes to assess safety and CMP-CPS-001 effect on ureagenesis.
• The company expects to initiate GLP toxicity studies for the SYNGAP1 program in 2025.
• The company plans to progress toward additional clinical trials and explore strategic partnerships.

Key Dates

Keywords

SYNGAP1, Urea Cycle Disorders, CMP-SYNGAP-01, CMP-CPS-001, Gene Therapy, Regulatory RNA, Haploinsufficiency, ASO, Clinical Trial, Protein Upregulation